Get started
Author

Nicolas Sommer

Observed names: N. Sommer, Sommer Nicolas, Sommer, Nicolas
Institution: Genentech
OpenAlex ID: A5026035409
Phase IB Study of Vemurafenib in Combination with Irinotecan and Cetuximab in Patients with Metastatic Colorectal Cancer with BRAF V600E Mutation
2016 · David S. Hong, Van K. Morris, et al. · Cancer Discovery · 219
Phase II Randomized Trial of Sequential or Concurrent FOLFOXIRI-Bevacizumab Versus FOLFOX-Bevacizumab for Metastatic Colorectal Cancer (STEAM)
2018 · Herbert I. Hurwitz, Benjamin R. Tan, et al. · The Oncologist · 82
PDF
Randomized trial of standard chemotherapy alone or combined with atezolizumab as adjuvant therapy for patients with stage III colon cancer and deficient mismatch repair (ATOMIC, Alliance A021502).
2019 · Frank A. Sinicrope, Fang-Shu Ou, et al. · Journal of Clinical Oncology · 64
Characterization of response to atezolizumab + bevacizumab versus sorafenib for hepatocellular carcinoma: Results from the IMbrave150 trial
2021 · Riad Salem, Daneng Li, et al. · Cancer Medicine · 59
Overall survival in patients with glioblastoma before and after bevacizumab approval
2017 · Derek R. Johnson, Antonio M. P. Omuro, et al. · Current Medical Research and Opinion · 40
Pertuzumab + trastuzumab for HER2-amplified/overexpressed metastatic colorectal cancer (mCRC): Interim data from MyPathway.
2017 · Herbert Hurwitz, Kanwal Pratap Singh Raghav, et al. · Journal of Clinical Oncology · 38
Randomized trial of FOLFOX alone or combined with atezolizumab as adjuvant therapy for patients with stage III colon cancer and deficient DNA mismatch repair or microsatellite instability (ATOMIC, Alliance A021502).
2017 · Frank A. Sinicrope, Fang-Shu Ou, et al. · Journal of Clinical Oncology · 35
Disease Monitoring Using Post-induction Circulating Tumor DNA Analysis Following First-Line Therapy in Patients with Metastatic Colorectal Cancer
2020 · Xiaoju Max Ma, Johanna C. Bendell, et al. · Clinical Cancer Research · 28
PDF
Patient and physician preferences for anticancer drugs for the treatment of metastatic colorectal cancer: a discrete-choice experiment
2017 · Juan Marcos González, Sarika Ogale, et al. · Cancer Management and Research · 25
PDF
Treatment Patterns and Outcomes in Patients with KRAS Wild-Type Metastatic Colorectal Cancer Treated in First Line with Bevacizumab- or Cetuximab-Containing Regimens
2017 · Arthur C. Houts, Sarika Ogale, et al. · Journal of Gastrointestinal Cancer · 15
Overall response rate (ORR) in STEAM, a randomized, open-label, phase 2 trial of sequential and concurrent FOLFOXIRI-bevacizumab (BEV) vs FOLFOX-BEV for the first-line (1L) treatment (tx) of patients (pts) with metastatic colorectal cancer (mCRC).
2016 · Johanna C. Bendell, Benjamin R. Tan, et al. · Journal of Clinical Oncology · 15
Single‐institution retrospective review of patients with recurrent glioblastoma treated with bevacizumab in clinical practice
2019 · Annick Desjardins, James E. Herndon, et al. · Health Science Reports · 13
PDF
Real-world Direct Health Care Costs for Metastatic Colorectal Cancer Patients Treated With Cetuximab or Bevacizumab-containing Regimens in First-line or First-line Through Second-line Therapy
2017 · Stephen Johnston, Kathleen Wilson, et al. · Clinical Colorectal Cancer · 11
A randomized phase II study of trastuzumab and pertuzumab (TP) compared to cetuximab and irinotecan (CETIRI) in advanced/metastatic colorectal cancer (mCRC) with HER2 amplification: S1613.
2018 · Kanwal Pratap Singh Raghav, Shannon L McDonough, et al. · Journal of Clinical Oncology · 9
Overall survival in patients with glioblastoma before and after bevacizumab approval.
2016 · Derek Richard Johnson, Antonio Marcilio Padula Omuro, et al. · Journal of Clinical Oncology · 7
Plasma-Based Measurements of Tumor Heterogeneity Correlate with Clinical Outcomes in Metastatic Colorectal Cancer
2022 · Stephanie J. Yaung, Christine Ju, et al. · Cancers · 6
PDF
Progression-Free Survival in Patients Receiving Chemotherapy Alone (C) or Chemotherapy with Bevacizumab (CB) for First-Line Treatment of KRAS Mutant Metastatic Colorectal Cancer in Community Oncology Settings
2017 · Arthur C. Houts, Sarika Ogale, et al. · Journal of Gastrointestinal Cancer · 5
Updated efficacy, safety, and biomarker analyses of STEAM, a randomized, open-label, phase II trial of sequential (s) and concurrent (c) FOLFOXIRI-bevacizumab (BV) vs FOLFOX-BV for first-line (1L) treatment (tx) of patients with metastatic colorectal cancer (mCRC).
2017 · Herbert Hurwitz, Benjamin R. Tan, et al. · Journal of Clinical Oncology · 5
Bevacizumab at first recurrence after standard radio-chemotherapy is associated with improved overall survival in glioblastoma patients with large tumor burden
2018 · Huy Tram Nguyen, Nhung Nguyen, et al. · Neuro-Oncology Practice · 4
PDF
Treatment patterns and outcomes in patients with KRAS wild type (WT) metastatic colorectal cancer (mCRC) treated in first line with bevacizumab (B) or cetuximab (C) containing regimens.
2016 · Arthur C. Houts, Sarika Ogale, et al. · Journal of Clinical Oncology · 4
STEAM: A randomized, open-label, phase 2 trial of sequential and concurrent FOLFOXIRI-bevacizumab (BEV) versus FOLFOX-BEV for the first-line (1L) treatment (tx) of patients (pts) with metastatic colorectal cancer (mCRC).
2014 · Johanna C. Bendell, Benjamin R. Tan, et al. · Journal of Clinical Oncology · 4
Correlation of measurements of tumor heterogeneity based on next-generation sequencing (NGS) of circulating tumor DNA (ctDNA) with clinical outcomes in STEAM, a prospective, randomized, multicenter study in metastatic colorectal cancer (mCRC).
2018 · Stephanie Yaung, Nalin Tikoo, et al. · Journal of Clinical Oncology · 1
Correlation of pre- and post-induction plasma mutant allele fraction with progression-free survival (PFS) in STEAM, a prospective, randomized, multicenter study in metastatic colorectal cancer (mCRC).
2017 · John J. Lee, John F. Palma, et al. · Journal of Clinical Oncology · 1
Abstract A36: Circulating cell-free DNA as a marker for response and resistance to BRAF and EGFR inhibition in BRAF-mutated metastatic colorectal cancer
2015 · Van Morris, Filip Janku, et al. · Molecular Cancer Therapeutics · 1
Patients' and physicians' risk-benefit trade-off preferences for metastatic colorectacl cancer treatments.
2015 · Juan Marcos Gonzalez, Robert Morlock, et al. · Journal of Clinical Oncology · 1
Works count: 38
Citation count: 695
H-index: 12
I10-index: 13
Year
Topic
Type